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AimsWe investigated the role of src family kinases (srcFK) in agonist-mediated Ca2þ-sensitization in pul-
monary artery and whether this involves interaction with the rho/rho-kinase pathway.
Methods and results Intra-pulmonary arteries (IPAs) and cultured pulmonary artery smooth muscle cells
(PASMC) were obtained from rat. Expression of srcFK was determined at the mRNA and protein levels.
Ca2þ-sensitization was induced by prostaglandin F2a (PGF2a) in a-toxin-permeabilized IPAs. Phosphoryl-
ation of the regulatory subunit of myosin phosphatase (MYPT-1) and of myosin light-chain-20 (MLC20) and
translocation of rho-kinase in response to PGF2a were also determined. Nine srcFK were expressed at the
mRNA level, including src, fyn, and yes, and PGF2a enhanced phosphorylation of three srcFK proteins at
tyr-416. In a-toxin-permeabilized IPAs, PGF2a enhanced the Ca
2þ-induced contraction (pCa 6.9) approxi-
mately three-fold. This enhancement was inhibited by the srcFK blockers SU6656 and PP2 and by the
rho-kinase inhibitor Y27632. Y27632, but not SU6656 or PP2, also inhibited the underlying pCa 6.9 con-
traction. PGF2a enhanced phosphorylation of MYPT-1 at thr-697 and thr-855 and of MLC20 at ser-19. This
enhancement, but not the underlying basal phosphorylation, was inhibited by SU6656. Y27632 sup-
pressed both basal and PGF2a-mediated phosphorylation. The effects of SU6656 and Y27632, on both
contraction and MYPT-1 and MLC20 phosphorylation, were not additive. PGF2a triggered translocation
of rho-kinase in PASMC, and this was inhibited by SU6656.
Conclusions srcFK are activated by PGF2a in the rat pulmonary artery and may contribute to Ca
2þ-sen-










Ca2þ-sensitization in smooth muscle is the process by which
increased myosin light-chain phosphorylation, and hence
contractile force, occurs, generated in response to an exter-
nal stimulus independently of changes in intracellular Ca2þ
concentration ([Ca2þ]i).
1 In smooth muscle, this is believed
to occur principally through phosphorylation of myosin-
binding subunit (or MYPT-1) and subsequent inhibition of
myosin light-chain phosphatase.2 MYPT-1 is phosphorylated
by rho-kinase at two sites (thr-697 and thr-855 in rat), the
first of which results in inhibition of phosphatase activity3
and the second results in dissociation of the phosphatase
from myosin.4 Rho-kinase is activated by binding to the
GTP-bound form of the small G-protein RhoA and subsequent
translocation.5 The mechanisms by which agonist stimu-
lation activates RhoA are not fully understood, but the invol-
vement of guanine nucleotide exchange factors (RhoGEF) is
a requirement.6
src family kinases (srcFK) are a group of closely related
non-receptor tyrosine kinases, the eponymous member of
which has been found to be highly expressed in vascular
tissues.7 srcFK are activated by myristoylation and/or palmi-
toylation,8 translocation to the plasma membrane,9 and sub-
sequent auto-phosphorylation at tyr-416.10 Tyrosine kinases
in general are implicated in vascular smooth muscle* Corresponding author. Tel: þ44 020 7848 4297; fax: þ44 020 7848 3743.
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contraction, both via actions upon Ca2þ release and/or
influx and via Ca2þ-sensitization.11–15 Although evidence
for the latter is somewhat contradictory,11,14 one study
clearly shows that sphingosylphosphorylcholine-mediated
contraction and translocation of rho-kinase in pig coronary
artery are dependent on srcFK.16 srcFK may regulate rho
activation via phosphorylation of RhoGEF.6
Ca2þ-sensitization and the rho/rho-kinase pathway are
important components of contractile function in pulmonary
artery, in response to agonists and acute or chronic hypoxia,
both in normal and patho-physiological settings,17,18
whereas the role(s) of srcFK are largely unexplored.19 In
the present study, therefore, we evaluated the role of
srcFK in Ca2þ-sensitization-dependent prostaglandin F2a
(PGF2a)-mediated contraction in rat small distal pulmonary
arteries and srcFK interaction with the rho/rho-kinase
pathway.
2. Methods
2.1 Animals, tissue isolation, and cell culture
This study conforms with the Guide for the Care and Use of Labora-
tory Animals published by the US National Institutes of Health (NIH
Publication No. 85–23, revised 1996). Male Wistar rats (200–250 g)
were killed by lethal overdose of pentobarbital (ip). Lungs were
excised and placed in cold physiological salt solution (PSS), and
first to third-order branches of the intra-pulmonary artery (IPA)
were dissected free of surrounding parenchyma. First, second,
and third-order branches (150–1000 mm diameter) were used for
the extraction of mRNA for polymerase chain reaction (PCR) and
protein for western blot experiments. Second or third-order
branches (150–600 mm diameter) were used for the preparation
of pulmonary artery smooth muscle cells (PASMC) and measurement
of isometric tension.
PASMC were dispersed enzymatically and grown in DMEM with 10%
FCS to passage 4 or 5. Cells were then growth-arrested in serum-free
media for 24 h and harvested for PCR/western blot or plated on
13 mm coverslips and then growth-arrested for staining and translo-
cation experiments. Identification of each line of cells as smooth
muscle was verified by positive staining with anti-smooth muscle
a-actin, and anti-calponin antibodies (Santa Cruz Biotechnology,
CA, USA).
2.2 Solutions, drugs, and chemicals
PSS contained (mM): NaCl 118; NaHCO3 24; KCl 4; CaCl2 1.8;
MgSO4 1; NaH2PO4 0.434, glucose 5.56. Ca
2þ-free relaxing solution
contained (mM): PIPES 30, Mg(Ms)2 5.3, KMs 46.6, K2EGTA 10,
Na2ATP 5, Na2 creatinine phosphate 10, and the pH was set at 7.1.
Ca2þ-containing intracellular solution was identical except for the
substitution of CaEGTA for K2EGTA. Free [Ca
2þ] was adjusted by
mixing the two solutions in the appropriate proportion, as calcu-
lated by WEBMAXC software (www.stamford.edu). SU6656, PP2,
PP3 and Y27632 were all obtained from Calbiochem (Merck
Biosciences Nottingham, UK). PGF2a (tromethamine salt) was pur-
chased from Biomol (Exeter, UK). All other reagents were obtained
from Sigma (Poole, UK) Calbiochem, Invitrogen (Paisley, UK), or
Fisher (Loughborough, UK).
2.3 RNA isolation and reverse transcriptase–
polymerase chain reaction
Total RNA was extracted from IPA or PASMC using the Qiagen RNeasy
mini kit and TissueLyser (Qiagen, Crawley, UK). RNA was treated
with TURBO DNase (Ambion, Austin, TX, USA) to remove any remain-
ing contaminating DNA and then reverse-transcribed in the presence
of RNAguard (GE Healthcare, Chalfont St Giles, UK) by using random
hexamers and revert-aid reverse transcriptase (Fermentas Inter-
national, York, UK). MacVectorTM (version 7.2) and Ensembl
Genome Browser (www.emsembl.org) were used to design RT–PCR
primer pairs. Sense and antisense primers on either side of a small
intron (,1 kb) were made to allow distinction from amplification
of any contaminating DNA as opposed to reverse-transcribed
mRNA. Primer pairs are as follows. BLK (accession no. BC098683):
sense GGACAATGGAGGCTATTACATCTCG; antisense ATTCTTCGGGG
CTGGGTTCACAC. FGR (accession no. BC062025): sense TCTATGC
TACTTGCTCACCGCAC; antisense ATAAATGGGTTCCTCTGACACCAC.
FRK (accession no. U09583): sense TGTGTGGTCTTTTGGAATCCTGC;
antisense TTGGTCGTTGCTTGGGCTCTAC. FYN (accession no.
U35365): sense GAAGAGCCCATTTACATTGTCACG; antisense
ATGAGTCCGTTCCCCACCAG. HCK (accession no. BC078890): sense
CTGGACAGTGGAGGCTTCTACATC; antisense ATGGCTTCTGGGG
TTTGGG. LCK (accession no. BC099218): sense TCCCCTCGTAT-
CACTTTTCCCG; antisense CCCTTGCTTCAGACTTTTCACTGC. LYN
(accession no. AF000300): sense GACAATCTGAATGACGATGGAG;
antisense CGTAGTTGCTGGGGATGAAGC. SRC (accession no.
AF157016): sense TTCAAGAAAGGGGAGCGGCTGC; antisense
TGTCAAAGTCGGATACAGAGAGGC. YES1 (accession no. BC079403):
sense GCAAAATGGGGAGAAAAGATGCTG; antisense TGGTCGTGATG
TAGTATCCACCG.
All PCR primers were supplied by MWG Biotech (Ebersberg,
Germany). PCR was carried out using 100 ng of reverse-transcribed
RNA, 1 PCR II buffer, 4 mM MgCl2, 2 U Amplitaq Gold (Applied Bio-
systems, Warrington, UK), 0.5 U Perfect Match (Stratagene Europe,
The Netherlands), 0.25 mM dNTPs (Fermentas International, York,
UK), and 1.25 mM primer pair in a final volume of 40 mL. PCR
cycling conditions were 10 min 958C followed by 4 cycles of 2 min
958C, 10 min 578C, 2 min 728C and then a variable number of
cycles of 2 min 958C, 2 min 578C, 2 min 728C (total number of
cycles indicated in figure legends). Eighty microlitres of PCR pro-
ducts (reaction equivalent on 20 ng reverse-transcribed RNA) were
analysed by electrophoresis on 2.8% agarose gels run in 1 TAE
buffer (National Diagnostics, Yorkshire, UK) with PhiX174 DNA/
HinfI Marker (Fermentas International, York, UK). Gel-purified PCR
fragments were sequenced to confirm identity (Geneservice,
Medical Solutions plc, UK).
2.4 Western blot
IPA segments were treated with PGF2a (20 mM), following a 15 min
equilibration period in PSS and a 15 min pre-incubation with
pharmacological agents where appropriate, gassed with 5% CO2/
balance air at 378C, prior to snap-freezing. Tissue was homogenized
and protein extracted in 50 mL of Tris/SDS sample buffer containing
phosphatase inhibitor cocktail I and II (Sigma) and protease inhibitor
cocktail I (Sigma). Protein was extracted from PASMC by the same
method. Protein extracts (12–15 mL, 10 mg, per lane) were run
on SDS/PAGE gels (4–12% gradient, Invitrogen), transferred to nitro-
cellulose membrane, blocked with 5% skimmed milk for 1 h, probed
with primary antibody (1:1000, in Tris-buffered saline with 0.1%
skimmed milk) overnight at 48C and then with horseradish-
peroxidase conjugated anti-IgG secondary antibody (1:5000 in
tris-buffered saline with 1% milk) for 1 h at room temperature.
For phosphorylation experiments, membranes were first probed
with anti-phospho-antibodies, stripped for 1 h (Pierce stripping
buffer), re-blocked, and re-probed with corresponding anti-total
antibodies. Protein bands were visualized with Supersignal West
Femto Maximum Sensitivity Substrate (Pierce, Cramlington, UK) or
ECL western blotting detection reagent (Amersham, Bucks, UK)
and exposed to photographic film. Rabbit anti-src, rabbit
anti-phospho-srcFK (tyr-416), mouse anti-phospho-tyrosine, rabbit
anti-myosin light-chain, mouse anti-phospho-myosin light-chain
(ser-19), and mouse anti-b-actin antibodies were obtained
from Cell Signaling. Sheep anti-MYPT-1, rabbit anti-phospho-
MYPT-1 (thr-695: equivalent to thr-697 in rat), and rabbit
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anti-phospho-MYPT-1 (thr-850: equivalent to thr-855 in rat) anti-
bodies were obtained from Upstate (UK).
2.5 Force measurement and a-toxin
permeabilization
IPAs were mounted on a Mulvany–Halpern wire myograph (DMT A/S,
Aarhus, Denmark), bathed in PSS (gassed with 95% air/5% CO2, pH
7.4), and stretched to 90% of the circumference necessary to
create an equivalent transmural pressure of 4.4 kPa (30 mmHg).
IPAs were equilibrated with three 3 min contractions to 80 mM
KþPSS and then permeabilized with a-toxin as follows. First,
arteries were equilibrated in relaxing solution (as mentioned
earlier) and then permeabilized by incubation at pCa 6.5 with
60 mg/mL a-toxin until the resulting vasoconstriction reached a
plateau. Following re-equilibration with relaxing solution, submaxi-
mal vasoconstriction was elicited with pCa 6.9, and then PGF2a
(100 mM) was applied, in the presence of 1 mM GTP to support
G-protein activation. All contraction experiments were conducted
at 268C and in the presence of 10 mM cyclopiazonic acid to
remove the influence of Ca2þ store release on contraction.
2.6 Staining and image analysis
PASMC were treated with 20 mM PGF for 10 min in DMEM at 378C with
or without prior application of 30 mM SU6656 for 10 min. Reactions
were terminated by addition of paraformaldehyde fixative. For
ROCK-2 translocation, fixed cells were permeabilized with
Triton-100 and stained overnight with anti-ROCK-2 primary antibody
(1:100, Santa Cruz Biotechnology) at 48C following incubation with
Alexa Fluor 488-labelled secondary antibody (1:1000, Santa Cruz)
for 1 h at room temperature. Specificity of anti-ROCK-2 was con-
firmed by western blot (single band at 160 kDa). Staining was nega-
tive with secondary antibody alone.
2.7 Data analysis and statistics
Images of western blot bands of appropriate molecular weights were
quantified using Image J software (rsb.info.nih.gov). Band intensity
was expressed as a ratio of phospho/total for each protein, and
values from each treated sample were normalized to those from
control (untreated) samples run on the same gel. Two to three
control samples were run on each gel and averaged. Statistical
analysis was performed with SigmaStat (Systat software Inc.). Time-
dependent drug responses were examined by two-way repeated
measures ANOVA with appropriate post-tests. Individual compari-
sons (e.g. single-dose PGF2a vs. control) were performed by Stu-
dent’s t-test or Mann–Whitney rank sum test, where appropriate.
Comparisons of the effects of different drugs or dose-responses of
single drugs against PGF2a were performed by one-way ANOVA
with post-tests or by Kruskal–Wallis one-way ANOVA on ranks with
post-tests, where appropriate.
3. Results
3.1 Expression of src family kinases
PCR was performed on mRNA extracts from IPA. All nine src
family members were expressed, and the three most abun-
dant are shown in Figure 1A (see Supplementary material
online, Figure Si for all nine). A similar expression pattern
was obtained from cultured rat PASMC (see Supplementary
material online, Figure Sii). srcFK were also expressed at
the protein level. Three bands were visualized, two at
59/60 kDa and one at 54 kDa. These correspond to the
three most highly expressed at the mRNA level, src, and
the closely related fyn and yes, with expected molecular
weights in rat of 60, 60, and 54 kDa, respectively (as
calculated from the predicted amino acid sequence at
www.bioinformatics.org). Representative blots are shown
in Figure 1B. Similar protein expression was obtained from
cultured rat PASMC (see Supplementary material online,
Figure Sii). In order to demonstrate full kinase activity,
srcFK require auto-phosphorylation at tyr-416.10
Phospho-srcFK (tyr-416) immunoreactivity was inhibited by
the srcFK inhibitor PP2 (at 3 and 30 mM but not at 0.3 mM)
but not by the inactive analogue PP3 (30 mM) (Figure 1B),
indicating in this preparation that 30 mM PP2 is required
to substantially inhibit srcFK auto-phosphorylation, and
hence srcFK activity.
3.2 src family kinases inhibition antagonizes
PGF2a-mediated Ca
21-sensitization
IPAs were permeabilized with a-toxin and submaximally
constricted with pCa clamped at 6.9. This constriction was
enhanced approximately three-fold by application of
PGF2a, reaching a maximum at 40–45 min. At this point,
the srcFK inhibitors SU6656 and PP2 or the inactive ana-
logue PP3 was applied. These treatments were compared
with parallel time controls in which drug was not applied.
DMSO vehicle controls (applied in the place of drug) were
indistinguishable from time controls (not shown). SU6656
(Figure 2A) and PP2 (Figure 2B) both caused significant
relaxation at 3 and 30 mM, and this was significantly
greater than the small degree of spontaneous run-down
shown by the time controls. PP3 also caused relaxation
at 30 mM, but this was significantly less than for PP2
(Figure 2C). SU6656-mediated relaxation was unaffected
by de-endothelialization (n ¼ 6) and was similar when
SU6656 was applied prior to the PGF2a (n ¼ 5) as when it
was added acutely (see Supplementary material online,
Figures Siii and Siv, respectively).
The srcFK inhibitors SU6656 and PP2 cannot distinguish
between different members of the src family. However src
may be distinguished by the manner in which it is modified
for insertion into the plasma membrane, a process required
for full kinase activity.8,20 src is simply myristoylated,
whereas other family members, including fyn and yes, are
also palmitoylated.8,21 We therefore evaluated the effects
of the acylation inhibitor 2-bromopalmitate and of ecosa-
pentaenoic acid (EPA, which selectively displaces palmitoy-
lated proteins from the membrane) on PGF2a-induced
Ca2þ-sensitization.8,20,21 When 100 mM 2-bromopalmitate
was applied to a pre-existing PGF2a-induced contraction, a
small additional transient contraction was caused, which
was followed by a large sustained relaxation (Figure 2D).
In contrast to this, 60 mM EPA caused a large sustained
additional contraction and no relaxation (288+66%
increase, P , 0.01 vs. time controls at 90 min, n ¼ 5).
3.3 PGF2a enhances src family kinases
auto-phosphorylation and protein
tyrosine phosphorylation
In order to test the hypothesis that PGF2a-mediated contrac-
tion was acting via srcFK activation and protein tyrosine phos-
phorylation, further western blot experiments were
performed in PGF2a-treated IPA with anti-phospho-srcFK
(tyr-416) and anti-phospho-tyrosine. As shown in Figure 3A,
srcFK phosphorylation at tyr-416 was enhanced by PGF2a in
a time-dependent manner. The two bands analysed (60 and
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54 kDa) showed significant peak enhancements at 2–5 min,
whereas at 60 kDa, a significant second-phase-sustained
enhancement at 30 min was apparent. Several protein
bands were visualized with anti-phospho-tyrosine in IPA: a
single intense band at 120 kDa, bands at 95 and
75 kDa, and a close collection of bands centred at
65 kDa (Figure 3B). This immunoreactivity was enhanced
by PGF2a, significantly inhibited by PP2, but unaffected by
PP3 (30 mM). Other fainter bands were present but were not
quantified.
3.4 PGF2a mediates Ca
21-sensitization via MYPT-1
and MLC20 phosphorylation
Western blot experiments were carried out for MYPT-1 (both
phospho-thr-697 and phosho-thr-855) and MLC20
(phospho-ser-19) in PGF-treated IPA. PGF2a significantly
enhanced phosphorylation of MYPT-1 at both thr-697
(Figure 4A) and thr-855 (Figure 4B), although this effect
was greater at thr-855. As expected, PGF2a also significantly
enhanced ser-19 phosphorylation on MLC20 (Figure 4C). With
both MYPT-1 at thr-855 and MLC20 at ser-19, the
Figure 1 Expression of src family kinases in intra-pulmonary artery. (A) mRNA expression by polymerase chain reaction for src, fyn, and yes. The examples
shown are representative of triplicate determinations. Thirty-two polymerase chain reaction cycles were carried out for each cDNA. Values in parentheses
indicate expected amplicon sizes in base pairs (bp). (B) Protein expression of src family kinases by western blot analysis of intra-pulmonary artery. Three
bands (two at 59/60 kDa, and one at 54 kDa) were visualized with anti-src and by anti-phospho-src family kinases (tyr-416). Phospho-src family kinases
(tyr-416) immunoreactivity at 60 and 54 kDa was inhibited by PP2 (3 mM, *P , 0.05, n ¼ 8 rats and 30 mM, P , 0.05, n ¼ 8 rats) but not by PP3 (30 mM, n ¼ 8 rats).
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Figure 2 Effect of src family kinase inhibitors on PGF2a-induced contraction in a-toxin-permeabilized intra-pulmonary artery. intra-pulmonary arteries were
pre-constricted with pCa6.9 for 30 min, prior to the addition of 100 mM PGF2a for 40 min (A–C) or 90 min (D). Compared with appropriate time controls (n ¼
12 arteries), this contraction was significantly relaxed by SU6656 [(A) 3 mM, 28+ 3%, *P , 0.05, n ¼ 8 arteries and 30 mM, 54+4%, *P , 0.01, n ¼ 8 arteries]
and by PP2 [(B) 3 mM, 25+5%, *P , 0.05, n ¼ 8 arteries and 30 mM, 46+5%, *P , 0.01, n ¼ 12 arteries]. PP3 also caused relaxation at 30 mM [(C) 28+ 2%,
*P , 0.05, n ¼ 12 arteries] but was significantly less effective than PP2 (†P , 0.05). 2-Bromopalmitate (2-BP) caused a transient contraction (non-significant)
followed by significant relaxation [(D) 100 mM, 71+4%, *P , 0.01, n ¼ 7 arteries, compared with time controls, n ¼ 7 arteries].
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PGF-stimulated increase in phosphorylation peaked at
10 min. This time point was therefore used in subsequent
phosphorylation experiments.
3.5 MYPT-1 and MLC20 phosphorylation are sensitive
to inhibition of src family kinases and rho-kinase
Basal phosphorylation of MYPT-1 at thr-697 and thr-855 and
MLC20 at ser-19 was not significantly affected by 30 mM
SU6656, but was reduced by the rho-kinase inhibitor
Y27632 (10 mM) (Figure 5A–C). Y27632 was much more
effective against MYPT-1 phosphorylation at thr-855 than
at thr-697. After 10 min exposure to PGF2a, phosphorylation
of MYPT-1 at thr-697 and thr-855 and MLC20 at ser-19 was
enhanced (Figure 5D–F). This PGF2a-induced enhancement
of MYPT-1 phosphorylation at thr-855 and MLC20 phosphory-
lation at ser-19 was nearly abolished by 30 mM SU6656
(Figure 5E and F). Y27632 also greatly inhibited the phos-
phorylation of these two sites. The effects of the two inhibi-
tors when used in combination were however not additive
(Figure 5D–F).
3.6 Interaction between src family kinases
and rho-kinase during PGF2a-mediated
Ca21-sensitization
The results shown in Figure 5 suggest that srcFK activation
may be part of the same pathway as PGF2a-induced
rho-kinase-mediated phosphorylation of MYPT-1. This was
corroborated by further contraction experiments in
a-toxin-permeabilized IPA. As expected, 30 mM SU6656 did
not have any significant effect on pCa 6.9-induced contrac-
tion in the absence of PGF2a (Figure 6A). PP2, PP3, and 2-
bromopalmitate were similarly without effect (PP2 and
PP3: 30 mM, n ¼ 8, 2-BP: 100 mM, n ¼ 5, not shown).
Y27632, however, did relax this contraction, indicative of
significant basal rho-kinase activity in the absence of
agonist (Figure 6A). Y27632 also greatly relaxed the PGF2a-
induced contraction, but this relaxation was not significantly
greater when SU6656 was applied simultaneously with
Y27632 (Figure 6B). The PKC-d selective blocker rottlerin
was completely without effect on PGF2a contraction (see
Supplementary material online, Figure Sv), eliminating the
possibility that our results were influenced by inhibition of
PKC-d by Y27632, as shown previously by Wilson et al.22
To examine more closely the interaction between srcFK
and rho-kinase during stimulation with PGF2a, we examined
in PASMC the subcellular translocation of rho-kinase,
a process that is required for its activation and therefore
precedes phosphorylation of MYPT-1.5 In control cells,
the majority of rho-kinase (ROCK-2, the isoform activated
by RhoA) antibody staining was localized to the nucleus;
with some cytoplasmic staining, but upon stimulation
with PGF2a, most of this translocated to the cytoskeleton.
This movement was almost completely reversed by
Figure 3 Effects of PGF2a on src family kinases tyr-416 auto-phosphorylation and tyrosine phosphorylation of multiple proteins in intra-pulmonary artery. (A)
PGF2a-enhanced phospho-src (tyr-416) immunoreactivity at 60 and 54 kDa in a time-dependent manner (20 mM, *P , 0.05, n ¼ 10–12 rats). (B) PGF2a also
enhanced phospho-tyrosine immunoreactivity at multiple protein bands (20 mM, *P , 0.01, n ¼ 10–15 rats). This was inhibited by PP2 (30 mM, †P , 0.05 vs.
PGF2a, n ¼ 10–15 rats) but not by PP3 (30 mM, n ¼ 12 rats). Data are expressed as the ratio of phospho-tyrosine/b-actin immunoreactivity.
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Figure 4 Effects of PGF2a on phosphorylation of MYPT-1 (120–130 kDa) and MLC20 (18 kDa) in intra-pulmonary artery. Phosphorylation was enhanced on MYPT-1
at thr-697 [(A) *P , 0.05, n ¼ 6–8 rats] and thr-855 [(B) *P , 0.05; **P , 0.01, n ¼ 6–10 rats] and on MLC20 at ser-19 [(C) *P , 0.05; **P , 0.01, n ¼ 6–11 rats].
Figure 5 Effects of inhibition of src family kinases and rho-kinase on MYPT-1 (120–130 kDa) and MLC20 (18 kDa) phosphorylation. [(A)–(C)] In the absence of
PGF2a, phosphorylation of all three sites was not affected by SU6656 (30 mM, n ¼ 7 rats), but variably inhibited by Y27632 (10 mM, *P, 0.05, n ¼ 8 rats).
[(D)–(F)] In the presence of PGF2a, phosphorylation of all three sites was enhanced (*P , 0.05; **P , 0.01, n ¼ 8–11 rats), and this enhancement was inhibited
by SU6656 (30 mM, MYPT-1 at thr-855 and MLC20 at ser-19, †P , 0.01, n ¼ 8 rats), Y27632 (10 mM, †P , 0.01, n ¼ 9 rats), and the two drugs in combination (†P ,
0.01, n ¼ 8 rats). No additive effect of SU6656 and Y27632 was apparent.
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pre-treatment with SU6656 (Figure 6C). In the absence of
PGF2a, SU6656 was without effect (not shown). No ROCK-2
was detected in plasma membrane.
4. Discussion
The results of this study clearly demonstrate the involve-
ment of srcFKs in agonist-induced contraction of the pul-
monary artery. Most previous works have relied on the use
of non-selective tyrosine kinase inhibitors such as genistein
and tyrphostins, which do not distinguish between receptor
and non-receptor tyrosine kinases, and have focused on the
role of these kinases in Ca2þ homeostasis (reviewed in Ward
et al.15). The few that have addressed the question of Ca2þ-
sensitization have drawn opposing conclusions. For example,
in a-toxin-permeabilized rat mesenteric arteries, ET-1-
induced contractions were inhibited by tyrphostin-A23,14
whereas in b-escin-permeabilized guinea-pig mesenteric
arteries, direct Ca2þ-mediated contraction was unaffected
by tyrphostin.11 This discrepancy may be explained by our
current findings, since we showed that the srcFK-selective
inhibitors SU665623 and PP224 both selectively inhibited
PGF2a-induced but not direct Ca
2þ-induced contraction in
a-toxin-permeabilized rat pulmonary artery and inhibited
PGF2a-mediated but not basal MLC20 phosphorylation at
ser-19, suggesting the involvement of srcFK only during
stimulation of G-protein-coupled receptors.
MYPT-1, the regulatory subunit of myosin phosphatase, is
an important mediator of changes in contractile force inde-
pendent of a change in [Ca2þ]i (Ca
2þ-sensitization).2 As has
been previously shown for PGF2a and other agonists in
other vascular preparations,22,25,26 we observed that PGF2a
enhanced MYPT-1 phosphorylation at two sites, thr-697
and thr-855 (the rat homologues of thr-696 and thr-850 in
humans), but it was principally phosphorylation at thr-855
which was most sensitive to rho-kinase inhibition by
Y27632. Although both threonine residues were previously
shown to be targets of rho-kinase,3,4 our results agree with
several other reports that thr-855 or its equivalent in
other vascular preparations is the principal target of rho-
kinase and that thr-697 is phosphorylated basally by
another as-yet-unspecified serine/threonine kinase.22,25,26
As with phosphorylation of MLC20, the enhancement of
MYPT-1 phosphorylation at thr-855 by PGF2a was inhibited
by SU6656 although basal phosphorylation was unaffected.
Interestingly, Y27632 nearly abolished the pCa 6.9-induced
contractions in IPA as well as the basal MYPT-1 phos-
phorylation at thr-855 and significantly inhibited MLC20
phosphorylation, suggesting that there is considerable
basal rho-kinase activity in the rat pulmonary artery.
In any case, it is stimulated further by the addition of
Figure 6 Interaction between src family kinases and rho-kinase activity in PGF2a-stimulated intra-pulmonary artery and pulmonary artery smooth muscle cells.
(A) In intra-pulmonary artery, in the absence of PGF2a, the pCa6.9 contraction was inhibited by Y27632 (10 mM, *P, 0.001, n ¼ 8, compared with time controls,
n ¼ 8 arteries) but not by SU6656 (30 mM, n ¼ 8 arteries). (B) Y27632 also inhibited contraction in the presence of PGF2a (10 mM, 84+2%, *P, 0.001, n ¼ 8
arteries) and this relaxation was unaltered by the additional presence of SU6656 (30 mM, 87+2%, *P , 0.001, n ¼ 8 arteries). The effect of SU6656 alone
(from Figure 2) is included as a comparison. (C) In pulmonary artery smooth muscle cells, PGF2a triggered translocation of rho-kinase (ROCK-2) immunoreactivity
from the nucleus to the cytoskeleton (20 mM, *P , 0.05, n ¼ 6 determinations) and this was prevented by SU6656 (30 mM; *P , 0.05, n ¼ 6 determinations).
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agonist. A similar observation was made in
U46619-stimulated rat caudal artery.22
The src family members most likely to be required for
the responses described in this study are the highly
expressed src and fyn, which have both been previously
implicated in smooth muscle contraction,7,16 and possibly
yes, which is also highly expressed. Unfortunately, existing
kinase inhibitors cannot easily distinguish between src,
fyn, or yes. However, these kinases do differ in the way
that they are post-translationally modified; src is dual-
myristoylated, whereas both fyn and yes are also palmi-
toylated.8 Previously, using inhibitors of fatty acid acylation
and palmitoylation, Nakao et al.16 suggested that
sphingosylphosphorylcholine-induced Ca2þ-sensitization in
porcine coronary artery was mediated specifically by fyn,
not src. We, however, found that the non-selective acylation
inhibitor 2-bromopalmitate, but not the selective palmitoy-
lation inhibitor EPA,21 inhibited PGF2a-mediated Ca
2þ-
sensitization. Accordingly, but bearing in mind that other
important membrane-signalling proteins are also myristoy-
lated and palmitoylated,27 we may tentatively suggest
that it is specifically src and not fyn or yes which is the
srcFK involved in PGF2a-mediated Ca
2þ-sensitization in rat
IPA. The additional contractions caused by 2-bromopalmi-
tate and EPA are presumably due to further actions of
these drugs, independent of PGF2a stimulation or srcFK
activity.
The question arises as to whether srcFK activation in
response to PGF2a is upstream of rho/rho-kinase or enhances
Ca2þ-sensitivity through a separate pathway. The actions of
SU6656 and Y27632 were not additive with respect to both
inhibition of PGF2a-induced MYPT-1 and MLC20 phosphoryl-
ation and inhibition of the associated PGF2a-induced con-
traction, suggesting that srcFK and rho-kinase may be part
of the same pathway. In order to test this hypothesis, we
examined translocation of rho-kinase in PASMC, a process
that is important for the activation of the kinase.5 In
control cells, rho-kinase staining was concentrated in the
nucleus, as has been shown previously,28 but upon PGF2a
treatment, it translocated to the cytoskeleton. Importantly,
this movement was reversed by pre-treatment with SU6656,
indicating that the movement of rho-kinase in response to
stimulation by PGF2a was likely to be mediated by srcFK.
In contrast to the study of Nakao et al.,16 we found no evi-
dence for the presence of rho-kinase at the plasma mem-
brane, either in control or in stimulated cells.
PGF2a mediates Ca
2þ-sensitization via the TP receptor,29
which is coupled to Gaq/11.
30 How this coupling results in
activation of srcFK and/or rho/rho-kinase is unclear. For
full kinase activity, srcFK require auto-phosphorylation at
tyr-41610 and we showed that this is enhanced by PGF2a,
indicating that srcFK activity was increased. Src activation
often goes hand in hand with focal adhesion kinase (FAK)
which is activated by src.31,32 FAK may be the 120 kDa
protein whose tyrosine phosphorylation in the current
study was enhanced by PGF2a and inhibited by PP2. A well-
established connection between G-protein-linked receptors
such as the TP prostenoid receptor (which is activated by
PGF2a
29) and mitogenic signalling involves src-dependent
transactivation of the EGF-receptor tyrosine kinase.33 This
mechanism also involves Gai, which is known to
activate src by direct coupling.34 Studies with the tyrosine
phosphatise inhibitor vanadate have suggested that RhoA
translocation is stimulated by as-yet-unspecified tyrosine
phosphorylation.35 Furthermore, a pathway for tyrosine
kinase-dependent modulation of rho activation has been
suggested: active rho requires GTP, and it acquires this
from rho-specific RhoGEF.6 Two RhoGEFs in native smooth
muscle that may enhance RhoA activation by Gaq or Ga12/
13 are leukaemia-associated RhoGEF (LARG) and
PDZ-RhoGEF,26,36 and LARG is indeed activated by tyrosine
phosphorylation.37
In conclusion, we have shown for the first time that
agonist-mediated, rho-kinase-dependent Ca2þ-sensitization
but not basal rho-kinase activity in rat pulmonary artery
requires srcFK activity. This has implications for the regu-
lation of rho and rho-kinase-dependent vascular tone and
vascular remodelling in health and disease. The precise
mechanism(s) by which G-protein-linked receptors couple
to srcFK and subsequent rho-kinase activation remain to
be determined.
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